[go: up one dir, main page]

CL2022001529A1 - Nuevos derivados de metilquinazolinona - Google Patents

Nuevos derivados de metilquinazolinona

Info

Publication number
CL2022001529A1
CL2022001529A1 CL2022001529A CL2022001529A CL2022001529A1 CL 2022001529 A1 CL2022001529 A1 CL 2022001529A1 CL 2022001529 A CL2022001529 A CL 2022001529A CL 2022001529 A CL2022001529 A CL 2022001529A CL 2022001529 A1 CL2022001529 A1 CL 2022001529A1
Authority
CL
Chile
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
CL2022001529A
Other languages
English (en)
Inventor
Dolente Cosimo
Stephen HEWINGS David
Hunziker Daniel
Krummenacher Daniela
Francesco Tommaso Pettazzoni Piergiorgio
Wichmann Juergen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2022001529A1 publication Critical patent/CL2022001529A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Harvester Elements (AREA)
  • Combines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I), o una sal farmacéuticamente aceptable de este. El compuesto de Fórmula (I) se puede utilizar como medicamento.
CL2022001529A 2019-12-10 2022-06-09 Nuevos derivados de metilquinazolinona CL2022001529A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10

Publications (1)

Publication Number Publication Date
CL2022001529A1 true CL2022001529A1 (es) 2023-02-10

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022001529A CL2022001529A1 (es) 2019-12-10 2022-06-09 Nuevos derivados de metilquinazolinona

Country Status (28)

Country Link
US (2) US12116349B2 (es)
EP (2) EP4483882A3 (es)
JP (2) JP7108146B2 (es)
CN (2) CN114787156B (es)
AR (1) AR122351A1 (es)
AU (1) AU2020403443B2 (es)
CA (1) CA3162883A1 (es)
CL (1) CL2022001529A1 (es)
CO (1) CO2022008968A2 (es)
CR (1) CR20220251A (es)
DK (1) DK4073065T3 (es)
ES (1) ES3023264T3 (es)
FI (1) FI4073065T3 (es)
HR (1) HRP20250418T1 (es)
IL (2) IL292161B2 (es)
LT (1) LT4073065T (es)
MA (1) MA58087B1 (es)
MX (1) MX2022006783A (es)
PE (1) PE20221778A1 (es)
PH (1) PH12022551119A1 (es)
PL (1) PL4073065T3 (es)
PT (1) PT4073065T (es)
RS (1) RS66721B1 (es)
SI (1) SI4073065T1 (es)
TW (2) TW202504895A (es)
UA (1) UA128299C2 (es)
WO (1) WO2021116055A1 (es)
ZA (2) ZA202204675B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
SI4073065T1 (sl) * 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
US12303509B2 (en) 2020-06-09 2025-05-20 Pfizer Inc. Compounds for the treatment of BRAF-associated diseases and disorders
AU2022289684A1 (en) * 2021-06-09 2023-10-05 F. Hoffmann-La Roche Ag Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
CN117460726A (zh) * 2021-06-09 2024-01-26 豪夫迈·罗氏有限公司 (3r)-n-[2-氰基-4-氟-3-(3-甲基-4-氧代-喹唑啉-6-基)氧基-苯基]-3-氟-吡咯烷-1-磺酰胺的新颖固体形式
EP4351577A1 (en) * 2021-06-09 2024-04-17 F. Hoffmann-La Roche AG Combination therapy for cancer treatment
WO2023008462A1 (ja) 2021-07-27 2023-02-02 東レ株式会社 癌の治療及び／又は予防のための医薬品
CN118201615A (zh) 2021-11-04 2024-06-14 豪夫迈·罗氏有限公司 喹唑啉酮化合物用于治疗癌症的新用途
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN120265291A (zh) 2022-11-18 2025-07-04 豪夫迈·罗氏有限公司 喹唑啉酮化合物的新用途和制剂
TW202440550A (zh) * 2022-12-15 2024-10-16 瑞士商赫孚孟拉羅股份公司 用於癌症治療之組合療法
WO2024126634A1 (en) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Process for the preparation of a quinazolinone derivative
WO2025008313A1 (en) 2023-07-04 2025-01-09 F. Hoffmann-La Roche Ag New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]- 3-fluoro-pyrrolidine-1-sulfonamide
WO2025108405A1 (zh) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 作为激酶抑制剂的喹唑啉酮衍生物的制备及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
CA2718123C (en) 2008-03-17 2017-08-22 Ambit Biosciences Corporation Quinazoline derivatives as raf kinase modulators and methods of use thereof
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
BR112015005982A2 (pt) 2012-09-19 2017-07-04 Novartis Ag di-hidropirrolidino-pirimidinas como inibidores de quinase
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
WO2016191296A1 (en) 2015-05-22 2016-12-01 Plexxikon Inc. Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases
TWI720032B (zh) * 2015-10-09 2021-03-01 比利時商葛萊伯格有限公司 Ｎ－磺醯化吡唑并﹝３，４－ｂ﹞吡啶－６－甲醯胺及其使用方法
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
WO2020142612A1 (en) 2019-01-03 2020-07-09 Genentech, Inc. Pyrido-pyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme i (ire i alpha) for the treatment of cancer diseases.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
PE20221027A1 (es) * 2019-12-10 2022-06-16 Hoffmann La Roche Nuevos inhibidores de braf como rompedores de la paradoja
SI4073065T1 (sl) 2019-12-10 2025-06-30 F. Hoffmann-La Roche Ag Novi derivati metilkinazolinona
US12303509B2 (en) 2020-06-09 2025-05-20 Pfizer Inc. Compounds for the treatment of BRAF-associated diseases and disorders
JP2023554442A (ja) 2020-12-18 2023-12-27 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規キナゾリノン誘導体
CN118561841A (zh) 2020-12-18 2024-08-30 豪夫迈·罗氏有限公司 新的芳基-吡啶并-嘧啶-酮衍生物
CN117940133A (zh) 2021-06-08 2024-04-26 C4医药公司 用于突变braf的降解的治疗剂
JP2024545073A (ja) 2021-12-08 2024-12-05 アレイ バイオファーマ インコーポレイテッド Ｎ－（２－クロロ－３－（（５－クロロ－３－メチル－４－オキソ－３，４－ジヒドロキナゾリン－６－イル）アミノ）－４－フルオロフェニル）－３－フルオロアゼチジン－１－スルホンアミドの結晶形態

Also Published As

Publication number Publication date
KR20220110554A (ko) 2022-08-08
US20220298119A1 (en) 2022-09-22
TW202504895A (zh) 2025-02-01
EP4073065A1 (en) 2022-10-19
TWI877268B (zh) 2025-03-21
CR20220251A (es) 2022-07-11
IL316473A (en) 2024-12-01
PT4073065T (pt) 2025-04-15
JP2022531609A (ja) 2022-07-07
DK4073065T3 (da) 2025-04-22
EP4073065B1 (en) 2025-02-19
LT4073065T (lt) 2025-04-25
IL292161B2 (en) 2025-04-01
AU2020403443A1 (en) 2022-05-12
CA3162883A1 (en) 2021-06-17
EP4483882A3 (en) 2025-03-05
UA128299C2 (uk) 2024-05-29
ZA202206923B (en) 2024-10-30
MA58087B1 (fr) 2025-04-30
PE20221778A1 (es) 2022-11-16
IL292161A (en) 2022-06-01
CN114787156B (zh) 2024-07-26
CN114787156A (zh) 2022-07-22
JP2022124458A (ja) 2022-08-25
AU2020403443B2 (en) 2023-02-23
WO2021116055A1 (en) 2021-06-17
HRP20250418T1 (hr) 2025-06-06
SI4073065T1 (sl) 2025-06-30
PH12022551119A1 (en) 2023-08-23
US12116349B2 (en) 2024-10-15
CO2022008968A2 (es) 2022-07-19
PL4073065T3 (pl) 2025-05-19
RS66721B1 (sr) 2025-05-30
AR122351A1 (es) 2022-09-07
MX2022006783A (es) 2022-07-11
IL292161B1 (en) 2024-12-01
TW202136245A (zh) 2021-10-01
ZA202204675B (en) 2022-12-21
EP4483882A2 (en) 2025-01-01
FI4073065T3 (fi) 2025-04-16
JP7108146B2 (ja) 2022-07-27
CN118791472A (zh) 2024-10-18
ES3023264T3 (en) 2025-05-30
US20240174621A1 (en) 2024-05-30
BR112022011123A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
CO2020014586A2 (es) Compuestos
CO2021016504A2 (es) Inhibidores de cdk
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR121226A1 (es) Compuestos y usos de estos
CO2021008681A2 (es) Inhibidor de 15-pgdh
UY35362A (es) Compuestos terapéuticos
UY37879A (es) Compuestos de bisamida que activan el sarcómero y sus usos
NI202000058A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
ES2572001T3 (es) Derivado de bisfurano antivírico como inhibidor de la proteasa del VIH e intermedios del mismo
UY37941A (es) Derivados de bencimidazol y sus usos
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
CY1123722T1 (el) Ενεσιμα φαρμακευτικα σκευασματα λεφαμουλινης
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
CO2022006965A2 (es) Inhibidores de egfr
CL2023001440A1 (es) Nuevos derivados de indazol acetileno
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.
AR116428A1 (es) Compuestos de 6-fluoro-2-metilbenzo[d]tiazol-5-ilo
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR104241A1 (es) Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
AR107310A1 (es) Inhibidores de tetrahidrocarbazol de receptores sirt1
AR115865A2 (es) Compuestos terapéuticos
AR125853A2 (es) Composición farmacéutica de una sal hemisulfato de un compuesto nucleotídico